Streetbeat News

CYBN

Cybin Inc.

https://www.cybin.com

Industry

Biotechnology

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Open

9.34

Mkt cap

191M

Volume

282K

High

9.57

P/E Ratio

-2.61

52-wk high

19.84

Low

9.01

Div yield

N/A

52-wk low

6.50

Wall Street analysts have set a consensus price target for Cybin Inc. (CYBN) that suggests a potential upside of 988.7%. Despite skepticism about the effectiveness of price targets, positive earnings estimate revisions could indicate a near-term stock price increase.

Portfolio Pulse from

February 17, 2025 | 4:00 pm

Wall Street analysts have set an average price target for Cybin Inc. (CYBN) that suggests a potential upside of 952.2%. This optimistic outlook is supported by positive trends in earnings estimate revisions, which could lead to a stock price increase.

Portfolio Pulse from

January 30, 2025 | 4:15 pm

Cybin Inc. has launched a strategic partnership with Segal Trials to support its Phase 3 program for CYB003, aimed at treating Major Depressive Disorder.

Portfolio Pulse from

January 15, 2025 | 5:30 pm

Cybin Inc. will participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025, with CEO Doug Drysdale engaging in a fireside chat.

Portfolio Pulse from

January 09, 2025 | 10:15 pm

Cybin Inc. will participate in the Water Tower Research Fireside Chat on December 11, 2024, with CEO Doug Drysdale and CMO Amir Inamdar representing the company. Cybin is focused on developing innovative treatments in neuropsychiatry.

Portfolio Pulse from

December 04, 2024 | 12:45 pm

Cybin Inc. has initiated a Phase 3 program named PARADIGM to evaluate CYB003 for treating Major Depressive Disorder. The company also reported its second-quarter financial results.

Portfolio Pulse from

November 13, 2024 | 12:45 pm

Cybin Inc. has secured a US patent for its CYB005 phenethylamines program, focusing on non-hallucinogenic treatments for CNS disorders. This patent supports Cybin's innovative development beyond its clinical tryptamine programs. The company is also advancing its CYB003 and CYB004 programs, with significant upcoming trials and results expected in 2024.

Portfolio Pulse from Vandana Singh

October 24, 2024 | 11:01 am

Cybin is evaluating non-hallucinogenic dosing of its preclinical candidate CYB005 for treating CNS disorders.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:00 am

Cybin has announced the grant of its first U.S. Composition of Matter Patent for its CYB005 phenethylamines program, marking a significant milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:00 am

The DEA is proposing significant increases in production quotas for marijuana compounds and psychedelics like psilocybin and ibogaine to support research and clinical trials. This move reflects growing interest in these substances for medical and scientific purposes.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 5:41 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.